The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo
- 318 Downloads
Melanoma is a malignant tumor and causes majority of deaths related to skin cancer. Fibroblast growth factor 2 (FGF2) greatly contributes to melanoma growth and progress. In this paper, we attempt to evaluate the therapeutic potential of FGF2-binding peptide (named P7) using as a potent FGF2 antagonist via exploration of its antitumor effect on melanoma in vitro and in vivo.
Cell viability was measured by WST-1. Cell cycle progression was determined by propidium iodide staining and flow cytometry. Western blotting was carried out to detect the activation of Erk1/2, P38, Akt, and MEK, and the expression of apoptosis-associated proteins. The influence of P7 on FGF2 internalization was assessed by separation of nuclear and cytoplasmic protein fractions followed by Western blotting. Female C57BL/6 mice bearing xenograft melanoma were established and used to evaluate the antitumor effect of P7 in vivo.
In this study, we first proved that P7 peptides significantly inhibited proliferation of FGF2-induced melanoma cell line B16-F10. Further investigations revealed that the mechanisms of P7 peptides inhibiting cell proliferation of melanoma cells stimulated with FGF2 in vitro involved cell cycle arrest at the G0/G1 phase, blockade of the activation of Erk1/2, P38, and Akt cascades, and inhibition of FGF2 internalization. Finally, treatment of P7 peptides in a murine melanoma model resulted in significant inhibition of tumor growth and angiogenesis in vivo, which was associated with blockade of mitogen-activated protein kinase signal activation, and suppression of the expressions of anti-apoptotic Bcl-2 protein and angiogenic factor in the melanoma tumors.
The FGF2-binding peptide with potent antiproliferation and anti-angiogenic activity may have therapeutic potential in melanoma.
KeywordsFGF2-binding peptide Proliferation Angiogenesis Melanoma
This work was supported by grants from the National Natural Science Foundation of China (30973671, 81071800), the Natural Science Foundation of Zhejiang Province of China (Y2090292), the Natural Science Foundation of Guangdong Province of China (9151064001000031), the Science and Technology Planning Project of Wenzhou (Y20090244), the Fundamental Research Funds for the Central Universities (X. P. Wu), Guangdong Provincial “Thousand-Hundred-Ten Talent Project” (X. P. Wu), and Guangdong Provincial Key Discipline in Biochemistry and Molecular biology.
Conflict of interest
All authors declare that there are no potential conflicts of interest.
- Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, Berking C, Moller H, Maczey E, Rassner G, Herlyn M, Garbe C (2003) Fibroblast growth factor-2 but not Mel-CAM and/or beta 3 integrin promotes progression of melanocytes to melanoma. Exp Dermatol 12(3):296–306. doi: 10.1034/j.1600-0625.2003.120310.x PubMedCrossRefGoogle Scholar
- Ribatti D, Vacca A, Ria R, Marzullo A, Nico B, Filotico R, Roncali L, Dammacco F (2003) Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer 39(5):666–674. doi: 10.1016/s0959-8049(02)00150-8 PubMedCrossRefGoogle Scholar
- Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM (1999) Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine. Cancer Res 59(19):4919–4926PubMedGoogle Scholar
- Tsunoda S, Nakamura T, Sakurai H, Saiki I (2007) Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci 98(4):541–548. doi: 10.1111/j.1349-7006.2007.00432.x PubMedCrossRefGoogle Scholar